RVMD
Revolution Medicines Inc - Ordinary Shares
Company Overview
| Mkt Cap | $11.79B | Price | $96.75 |
| Volume | 1.20M | Change | +0.00% |
| P/E Ratio | -19.7 | Open | $98.99 |
| Revenue | $561.0K | Prev Close | $96.75 |
| Net Income | $-600.1M | 52W Range | $29.17 - $124.49 |
| Div Yield | N/A | Target | $130.81 |
| Overall | 44 | Value | 40 |
| Quality | 47 | Technical | 45 |
No chart data available
About Revolution Medicines Inc - Ordinary Shares
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Latest News
LifeSci Capital Sticks to Its Buy Rating for Revolution Medicines (RVMD)
Revolution Medicines (RVMD) Receives a Buy from Guggenheim
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RVMD | $96.75 | 0% | 1.20M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Revolution Medicines Inc - Ordinary Shares Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW